Rebyota denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for rebyota are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rebyota as Experimental — and Why You Can Appeal

Rebyota (fecal microbiota, live-jslm) received full FDA approval — not accelerated or provisional clearance — specifically for reducing the recurrence of Clostridioides difficile (C. diff) infection in adults following antibiotic treatment. An "experimental or investigational" denial at this stage is an outdated policy classification that has not been updated to reflect FDA approval status. This is one of the strongest categories of denial to appeal because a product that has received full FDA approval cannot, by definition, be experimental for its approved indication.

## Why This Denial Is Appealable

Insurers are not required to cover every FDA-approved drug, but classifying an FDA-approved product as "experimental" is legally and factually incorrect for the approved indication. Most insurer experimental/investigational policies explicitly exclude FDA-approved drugs from that classification. Cigna's own medical coverage policy likely contains language that FDA approval removes a therapy from investigational status — obtaining and citing that language directly is a powerful appeal tool. Additionally, relevant professional society guidelines (e.g., from the Infectious Diseases Society of America) have addressed microbiome-based therapies for recurrent C. diff; your prescriber can reference the applicable guidance generically.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice. Under ERISA Section 503, you are entitled to the specific clinical criteria and evidence Cigna used to classify Rebyota as experimental.
• ACA Section 2719 external review: For non-grandfathered plans, independent external review is available after exhausting internal remedies. The standard window is approximately 4 months from the final internal denial. An independent reviewer will apply objective clinical standards — and FDA approval status will weigh heavily.
• Expedited review: Available if your health would be seriously jeopardized by the standard timeline.

## Appeal Timeline

1. Obtain the specific policy language Cigna used to classify Rebyota as experimental. 2. Verify the current FDA approval status of Rebyota in the FDA's public drug database. 3. File the internal appeal with the FDA approval documentation and prescriber letter. 4. If denied, file for external review immediately.

## Documentation to Gather

• FDA approval documentation: The FDA approval letter or the current prescribing information confirming full approval for the relevant indication.
• Diagnosis and treatment history: Records documenting recurrent C. diff episodes, prior antibiotic courses, dates, and outcomes.
• Prescriber medical-necessity letter: Should cite the FDA-approved indication, reference applicable professional society guidelines, and directly address why Rebyota is not experimental for this patient.
• Cigna's own policy language: Request the current version; it likely exempts FDA-approved drugs from the experimental classification.

## Criteria-Mapping Structure

Obtain Cigna's experimental/investigational coverage policy. Map each criterion:

| Cigna Experimental Criterion | Response / Evidence | |---|---| | Is the drug FDA-approved for the proposed use? | Yes — cite FDA approval date and indication | | Does professional society guidance support use? | Cite applicable IDSA or relevant society guideline (without specific numbers) | | Is the use consistent with the approved label? | Prescribing information confirms; prescriber letter affirms |

A focused, well-documented internal appeal citing FDA approval status resolves this type of denial frequently at the first level.